Unilife Corp. has signed a long-term contract with Sanofi to supply Unifill Finesse, a customized device from its Unifill platform of prefilled syringes with automatic needle retraction for use with Lovenox and Clexane. The contract period can extend to 2024.
Unilife has granted Sanofi the exclusive use of the Unifill Finesse with anti-thrombotic drugs during the contract period. Sanofi will maintain exclusivity, subject to purchasing a minimum of 150 million units of the Unifill Finesse or other Unifill syringes per year. Unilife can supply its Unifill syringes to additional customers in all other therapeutic classes outside of anti-thrombotics. Unilife may also receive as much as $15 million in milestones, with $5 million expected in 2013.
Alan Shortall, chief executive officer of Unilife, remarked, “Our Unifill syringes set a new standard for the delivery of all prefilled biologics, drugs and vaccines. Like other game-changing products in our broad device portfolio, the distinctive visual, safety and functional benefits of Unifill can be leveraged by pharmaceutical customers to enhance and differentiate their injectable therapies. We thank the Sanofi Industrial organization for their innovative vision and their support, and look forward to a long-term partnership.”
Unilife Signs Long-Term Supply Pact with Sanofi
Published September 9, 2013
blog comments powered by Disqus